Pulpitis
Drug research and approvals for pulpitis: what is recruiting, what Health Canada authorized, FDA orphan designations and EU medicines. See every condition.
As of Nov 17, 2026, 54 studies of pulpitis are recruiting on ClinicalTrials.gov, and Health Canada has authorized 0 drug trials for it since 2013.
- Recruiting worldwide: 54
- Trials authorized in Canada: 0
- FDA orphan approvals: 0
- EU medicines: 0
Recruiting Now
Newest start dates first, of 54 recruiting on ClinicalTrials.gov ↗- Comparison Of Acetaminophen, NSAIDs, And Trypsin-Chymotrypsin Plus Acetaminophen For Post-Endodontic Pain After…NCT07759349 · Early Phase 1 · Dow University of Health Sciences · starts Aug 2, 2026
- Evaluation of the Effect of Different Irrigation Activation Methods During Endodontic RetreatmentNCT07779148 · Not applicable · Minia University · starts Aug 1, 2026
- Child's Behavior Using Single Rotary File System Versus Manual Instrumentation in Pulpectomy of Primary MolarsNCT07415694 · Not applicable · Cairo University · starts Jul 25, 2026
- Effect of Cryotherapeutic and Nanotherapeutic Sodium Hypochlorite on Post-Operative Endodontic Pain.NCT07923669 · Not applicable · October 6 University · starts Jul 1, 2026
- Comparative Evaluation of Post Obturation Pain After Root Canal Treatment Using Tricalcium Silicate vs Resin-Based…NCT07388368 · Not applicable · Armed Forces Institute of Dentistry, Pakistan · starts Jul 1, 2026
- Local Dexamethasone Administration in Symptomatic Irreversible PulpitisNCT07672873 · Not applicable · Marmara University · starts Jun 15, 2026
- Impact of Cross-Sectional Design in Single-File Rotary System on Apical Debris ExtrusionNCT07808684 · Not applicable · Minia University · starts Jun 1, 2026
- Effect of Ultrasonic and Diode Laser Activated Irrigation on Postoperative Pain Following Root Canal TreatmentNCT07906808 · Not applicable · October 6 University · starts Jun 1, 2026
- Postoperative Pain After Root Canal Treatment Using Different Root Canal SealersNCT07608939 · Not applicable · European University of Lefke · starts May 16, 2026
- Laser-Assisted vs Conventional Total Pulpotomy in Symptomatic Irreversible PulpitisNCT07850258 · Not applicable · meliksahgunduz · starts May 1, 2026
Drug Pipeline
4 in phase 3, 12 in phase 2, 4 in phase 1 or earlier; from ChEMBL's drug indications, furthest stage reached for this condition- Ibuprofen
- Phase 3 Cyclooxygenase inhibitor
- Epinephrine
- Phase 3 Adrenergic receptor agonist
- Lidocaine
- Phase 3 Sodium channel alpha subunit blocker
- Articaine
- Phase 3 Sodium channel alpha subunit blocker
- Ketorolac
- Phase 2 Cyclooxygenase inhibitor
- Diclofenac
- Phase 2 Cyclooxygenase inhibitor
- Acetaminophen
- Phase 2 Cyclooxygenase inhibitor
- Aceclofenac
- Phase 2 Cyclooxygenase-2 inhibitor
- Bupivacaine
- Phase 2 Sodium channel protein type IV alpha subunit blocker
- Fentanyl
- Phase 2 Mu opioid receptor agonist
- Sufentanil
- Phase 2 Mu opioid receptor agonist
- Bromelains
- Phase 2 Unknown
- Polihexanide
- Phase 2 Cell membrane disrupting agent
- Mannitol
- Phase 2 Unknown
- Hypochlorous acid
- Phase 2
- Poliglusam
- Phase 2
- Dexamethasone
- Phase 1 Glucocorticoid receptor agonist
- Zinc oxide
- Early phase 1 Sunscreen/skin protectant
- Alcohol
- Early phase 1
- Ferric sulfate
- Early phase 1
How Its Trials Ended
288 ClinicalTrials.gov studies of the condition, classified by TrialPanorama, partly automatically, so some labels are wrongOf the 15 whose ending is known, 60% met their primary endpoint, 0% missed it and 40% stopped early.
- Completed, result not reported13647%
- Ongoing7225%
- Status unknown6523%
- Met its primary endpoint93%
- Stopped: other or unclear52%
- Stopped: lack of efficacy10%
Condition names come from Health Canada's trial database. Orphan designations and EU medicines are matched when their indication names the condition as whole words, so a broader or differently worded indication can be missed. Recruiting counts are live from ClinicalTrials.gov's own condition search, refreshed daily. ClinicalTrials.gov, Health Canada Clinical Trials Database, FDA orphan designations, EMA